Author: Matthew Nelson|| Date Published: December 20, 2019
The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.
HHS said Wednesday its Biomedical Advanced Research and Development Authority will provide technical services and funds to help Paratek carry out research and manuacturing efforts for the Nuzyra drug, generically known as omadacycline.
The contract marks the department’s first award under Project BioShield, which incentivizes pharmaceutical companies to produce medical products meant to help the government counter biological, chemical, radiological and nuclear threats.
The Food and Drug Administration approved oral and intravenous forms of Nuzyra for adults who suffer from community-acquired pneumonia and acute skin infection.
Boston-based Paratek aims to secure emergency use authorization for antibiotic treatment of anthrax lung infections. BARDA will buy an initial supply if the company obtains FDA approval for expanded use of the drug.
The Naval Information Warfare Center Pacific is soliciting proposals for the development and fielding of intelligence, surveillance and reconnaissance systems…
The Department of War is accelerating its push into unmanned systems, moving beyond experimentation toward large-scale production, streamlined acquisition and…
BAE Systems has received a $117.7 million contract modification from the U.S. Navy to support depot-level modernization, maintenance and repair of USS…
Advanced wireless infrastructure is becoming as strategically important as artificial intelligence in modern defense operations 5G standalone enables network slicing,…
